Long-acting injectable cabotegravir for the prevention of HIV infection
Purpose of review This review highlights the development of long-acting injectable cabotegravir (CAB LA) for HIV preexposure prophylaxis (PrEP), with a focus on phase 2 studies and later development. Recent findings Early studies of CAB LA for HIV prevention offered promising pharmacokinetic data and paved the way for phase 2 studies, which have now been completed. On the basis of phase 2 data, dosing of CAB LA at 8-week intervals consistently delivers target trough concentrations in both men and women. Recent studies have shown no required dose adjustments for hepatic or renal disease and minimal drug--drug interactions. Additionally, injectable PrEP is desired by potential PrEP candidates. Still, gaps in knowledge remain with respect to implementation and delivery, the clinical significance of the pharmacologic tail, and dosing in key populations. Phase 3 trials are underway that are anticipated to inform some of these questions and provide efficacy and safety data to support regulatory submissions for CAB LA as a potential PrEP agent. Summary Recent studies have defined an appropriate CAB LA dosing interval and offered insight into its safety profile. Phase 3 studies will provide much-anticipated efficacy data. If efficacious, CAB LA may provide a desirable PrEP option for those who face challenges to daily pill adherence. A more complete understanding of how to best integrate LA PrEP into service delivery models will be critical for success.
Publication date: Available online 16 January 2020Source: Biocybernetics and Biomedical EngineeringAuthor(s): Julian Andres Ramirez-Bautista, Jorge Adalberto Huerta-Ruelas, László T. Kóczy, Miklós F. Hatwágner, Silvia L. Chaparro-Cárdenas, Antonio Hernández-ZavalaAbstractLoad distribution analysis on foot surface allows knowing human mechanical behavior and aids the doctor in the detection of gait disorders like, the risk of foot ulcerations, leg discrepancy, and footprint alterations. Plantar pressure data combined with techniques that use integral reasoning produce easy un...
On this episode of ASHA Voices, we dive into the research behind hearing loss reversal. While investigating a genetic form of hearing loss affecting transduction, researcher Jeff Holt found he could successfully reverse hearing loss in mice. How did the researcher test the rodents’ hearing? By unexpectedly playing loud music and looking for a response in the subjects, nicknamed Beethoven mice. “A deaf mouse doesn’t jump at all, no matter how loud a sound you play. But after introducing our gene therapy into the ears of Beethoven mice, we find they jump again,” says Holt. Also on the show, sens...
Nationwide improvements in insurance coverage and access to care seen, even in nonexpansion states
This report describes that human immunodeficiency virus partner services for transgender women must address social and structural barriers unique to this population.
Doubling the dose of influenza vaccine for pregnant women with HIV moderately improves immunogenicity compared to a single flu shot, but response remains well below that of pregnant women without HIV, a clinical trial shows.Reuters Health Information
[Daily Maverick] You're far more likely to be offered an HIV test at a government health facility than at your GP or workplace clinic.
[The Herald] MANICALAND Province has made strides in the fight against HIV, amid indications the prevalence rate has declined compared to the national rate, a development attributed to awareness and access to treatment.
[FrontPageAfrica] Southeastern Liberia -About 73 representatives of local county authorities, Ministry of Health, County Health Officers; the private sector; faith-based organizations; traditional leaders; civil society groups; human rights groups; community-based organizations, key populations to TB/HIV, women-based groups, persons living with HIV; people who are most vulnerable to and affected by the diseases drawn from three of Liberia's 15 political subdivisions, Sinoe, Rivercess, Grand Gedeh have completed a two-day regional country dialogu
We described ART initiation characteristics and the probability of mortality, loss to follow-up (LTFU) and transfer out after 6 months on ART and assessed factors associated with mortality and LTFU. Results: A total of 1847 infants started ART at a median age of 60 days [interquartile range: 29–77] and CD4 percentage (%) of 27% (18%–38%). Across ART initiation calendar periods 2006–2009 to 2013–2017, ART initiation age decreased from 68 (53–81) to 45 days (7–71) (P